Similar articles

• Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

  Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Ikeda M, et al. J Gastroenterol. 2005 Feb;40(2):148-56. doi: 10.1007/s00535-004-1519-2. J Gastroenterol. 2005. PMID: 15770398
• [Histological findings in the liver in patients with chronic hepatitis C].

  Takase K, Shiraki K. Takase K, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):434-8. Nihon Rinsho. 2004. PMID: 15359838 Review. Japanese. No abstract available.
• 'Yes, now you are free from chronic HCV infection, but . . .'.

  Toyoda H, Kumada T. Toyoda H, et al. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):9-10. doi: 10.1111/j.1440-1746.2005.04207.x. J Gastroenterol Hepatol. 2006. PMID: 16706803 No abstract available.
• [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].

  Nishiguchi S, Kubo S, Shiomi S. Nishiguchi S, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4. Nihon Rinsho. 2004. PMID: 15359868 Review. Japanese. No abstract available.
• [Chronic hepatitis C in hemodialysis patients].

  Tanaka H, Ueda H, Ichinose M, Miyano M. Tanaka H, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):645-8. Nihon Rinsho. 2004. PMID: 15359877 Review. Japanese. No abstract available.